HC Wainwright Adjusts Price Target for Capricor Therapeutics to $24.00, Retains "Buy" Rating.

Capricor Therapeutics (CAPR) maintains a "Buy" rating from HC Wainwright & Co., with a lowered price target from $77 to $24, a 68.83% decrease. Analysts forecast an average target price of $34.60, implying a 346.46% upside from the current price. The estimated GF Value for CAPR in one year is $11.23, suggesting a 44.91% upside.

Capricor Therapeutics (CAPR) recently received a complete response letter from the FDA regarding deramiocel, its cell therapy under development for cardiomyopathy in Duchenne muscular dystrophy patients. Despite this setback, analysts at H.C. Wainwright have maintained a "Buy" rating on the stock, although they have significantly lowered their price target from $77 to $24, a 68.83% decrease.

The FDA's response letter has not deterred analysts, who remain optimistic about the potential approval of deramiocel. The company has a strong safety record, with over 700 infusions treating more than 250 patients. Analysts at H.C. Wainwright project that approval may now occur in 2026 instead of 2025.

The average target price for Capricor Therapeutics Inc (CAPR) stands at $34.60, according to 10 analysts, implying a 346.46% upside from the current price of $8.52. The estimated GF Value for CAPR in one year is $11.23, suggesting a 44.91% upside.

Capricor Therapeutics has a robust cash position with approximately $145 million, providing a financial runway into 2027 without additional cash infusions. The company is transitioning from a translational medicine company to a commercial stage entity, actively working with its commercial partner NS Pharma on launch readiness in the United States. Additionally, Capricor is expanding its manufacturing capabilities, with plans to operationalize additional clean rooms by mid to late 2026 to meet potential demand.

However, Capricor faces challenges. Revenues for the first quarter of 2025 were zero, compared to approximately $4.9 million in the first quarter of 2024. Operating expenses have increased, with research and development expenses rising to approximately $16.2 million in Q1 2025 from $10.1 million in Q1 2024. The net loss for the first quarter of 2025 was approximately $24.4 million, compared to a net loss of $9.8 million in the first quarter of 2024.

There is uncertainty regarding the outcome of the FDA advisory committee meeting, which could impact the approval process for deramiocel. Additionally, negotiations for European distribution with Nippon Shinyaku have been extended, indicating potential delays or challenges in finalizing agreements for the European market.

References:
[1] https://www.gurufocus.com/news/2972452/capricor-therapeutics-capr-maintains-optimism-despite-fda-setback-capr-stock-news
[2] https://www.gurufocus.com/news/2972451/capricor-therapeutics-capr-maintains-buy-rating-amid-fda-feedback-capr-stock-news
[3] https://stockinvest.us/stock/CAPR